title: Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis.
authors.affiliation: Poliklinik für Rheumatologie, Hiller Research Unit for Rheumatology, Moorenstraße 5, 40225, Düsseldorf, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Weber
authors.affiliation: Poliklinik für Rheumatologie, Hiller Research Unit for Rheumatology, Moorenstraße 5, 40225, Düsseldorf, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Pongratz
authors.affiliation: Poliklinik für Rheumatologie, Hiller Research Unit for Rheumatology, Moorenstraße 5, 40225, Düsseldorf, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Schneider
authors.affiliation: Poliklinik für Rheumatologie, Hiller Research Unit for Rheumatology, Moorenstraße 5, 40225, Düsseldorf, Germany. ralph.brinks@med.uni-duesseldorf.de.
authors.forename: R
authors.initials: R
authors.lastname: Brinks
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid; D003362:Cost-Benefit Analysis; D000068800:Etanercept; D006801:Humans; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept